Amarin Corporation plc (ADR) (AMRN), AstraZeneca plc (ADR) (AZN), Omthera Pharmaceuticals Inc (OMTH): Three Stocks Near 52-Week Lows Worth Buying

Where PBF offers investors a really intriguing value is in its expansionary efforts on the East Coast and the mid-Continent. Specifically, crude-by-rail deals signed with Burlington Northern Santa Fe and Norfolk Southern Corp. (NYSE:NSC) in the mid-Continent should allow for increased deliveries and quicker per-day barrel output .

On a valuation basis, there are few refiners as inexpensive as PBF which is trading at just five times forward earnings and less than last year’s free cash flow! This sort of valuation would be realistic if the company were in distress or oil were at $30 a barrel, but make absolutely no sense based on the fact that PBF is growing refining capacity and orchestrating oil-by-rail deals with regularity. With nearly a 5% yield, this is a refiner that is certainly worth a deeper dig.

Foolish roundup
This week’s theme is all about whether or not things are really as bad as investors’ emotions make them out to be. Amarin Corporation plc (ADR) (NASDAQ:AMRN) clearly has competitive concerns, Equity Residential has misconstrued homebuilder associations to deal with, and PBF has to contend with tough East Coast crack spreads. Overall, though, all three companies are on solid footing for the future, and the thesis behind owning each one remains intact until further notice.

I’m so confident that these three names will bounce off their lows that I’m going to make a CAPScall of outperform on each one.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.